Ligand Pharmaceuticals
LGND · NASDAQ
Bulios Fair Price
$201.44
30.6% downside
Trenutna cena
$290.07
Po podatkih Bulios Fair Price je delnica LGND trenutno precenjena glede na svojo tržno ceno. Kako deluje?
Bulios Fair Price je ocena poštene vrednosti delnice iz Buliosovega modela vrednotenja. Je vhod za vašo lastno analizo, ne naložbeno priporočilo. Kako deluje?
Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več
O podjetju
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) is a San Diego-based biopharmaceutical company specializing in the development and acquisition of technologies that support the discovery and development of new therapeutics. The company generates revenue by licensing its Captisol® platform to biotech partners and manages a diversified portfolio of over 100 licensed programs across various therapeutic areas and development stages. In July 2024, Ligand announced the acquisition of APEIRON Biologics AG for $100 million, securing royalty rights to the commercial oncology drug QARZIBA®, designed for the treatment of high-risk neuroblastoma. Financial results for the second quarter of 2024 showed revenues of $41.5 million, surpassing analysts' expectations. The company plans to release its fourth quarter and full-year 2024 financial results on February 27, 2025.
V vašem jeziku še ni na voljo, zato je besedilo v angleščini.
Sector
Healthcare
Industry
Biotechnology
CEO
Todd C. Davis
Employees
47
Headquarters
Jupiter
Prihajajoči dogodki
Earnings
Upcoming earnings report